Clinical Trial Update: Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated gastrointestinal damage after administration of PL3100 versus naproxen in at-risk adults; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Ulcer
• Gastric Ulcer

Drugs mentioned

• Naproxen (Naproxen)
• PL3100

Snippet

Sponsor: PLx Pharma | Conditions: Gastroduodenal Ulcerations, Erosion | Phase 2 | Status: COMPLETED | Results posted: 2016-04-11